Long-term data from the Phase III APHINITY study support the use of a Perjeta-based regimen in HER2-positive early breast cancer.
The study examines a combination of Roche’s (ROG: SIX) Perjeta (pertuzumab) and Herceptin (trastuzumab), with chemotherapy, compared with Herceptin and chemo plus a placebo.
People in the trial were given treatment after surgery, and were deemed to be at high risk of recurrence. Globally, more than 500,000 people who fit into this category have received the Perjeta-based regimen, indicating the scale of the treatment opportunity for Roche.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze